MedTrace Logo

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

NCT05251727 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2024-08-19

No results posted yet for this study

Summary

To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab

Conditions

  • Chemotherapy-induced Peripheral Neuropathy

Interventions

DRUG

thrombomodulin alfa

Weight based dose of reconstituted treatment

DRUG

Placebo

Weight based dose of reconstituted treatment

Sponsors & Collaborators

  • Veloxis Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Libbie McKenzie, MD FASN · Veloxis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-24
Primary Completion
2024-06-05
Completion
2024-06-05
FDA Drug
Yes

Countries

  • United States
  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05251727 on ClinicalTrials.gov